Category
Dr
James
Watson
Associate Director
Co-Lead Malaria Chemoprevention Theme
Email
Research Theme
Malaria
Chagas
WWARN
James Watson joined IDDO in March 2023 as Associate Director.
He is a Sir Henry Dale Fellow funded by the Wellcome Trust working on improving the diagnosis and treatment of severe falciparum malaria.
James is a statistician by training and previously worked at the Mahidol Oxford Tropical Medicine Research Unit in Bangkok for seven years before moving to the Oxford University Clinical Research Unit in Viet Nam.
His research interests also include the radical cure of Plasmodium vivax malaria, SARS-CoV-2 antivirals, Chagas disease, snakebite and adaptive trial design.
All Publications
Population heterogeneity in Plasmodium vivax relapse risk.
Stadler, E., Cromer, D., Mehra, S., Adekunle, A., Flegg, J., Anstey, N., Watson, J., Chu, C., Mueller, I., Robinson, L., Schlub, T., Davenport, M., & Khoury, D. (2022). PLoS Neglected Tropical Diseases, 16(12), e0010990.
The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: an individual patient data meta-analysis
Watson, J., Commons, R., Tarning, J., Simpson, J., Llanos Cuentas, A., Lacerda, M., Green, J., Koh, G., Chu, C., Nosten, F., Price, R., Day, N., & White, N. (2022). ELife, 11.
The prognostic and diagnostic value of intraleukocytic malaria pigment in patients with severe falciparum malaria
Srinamon, K., Watson, J., Silamut, K., Intharabut, B., Phu, N., Diep, P., Lyke, K., Fanello, C., von Seidlein, L., Chotivanich, K., Dondorp, A., Day, N., & White, N. (2022). Nature Communications, 13.
Substantial misdiagnosis of severe malaria in African children.
White, N., Watson, J., Uyoga, S., Williams, T., & Maitland, K. (2022). Lancet (London, England), 400(10355), 807.
BIRC6 modifies risk of invasive bacterial infection in Kenyan children
Gilchrist, J., Kariuki, S., Watson, J., Band, G., Uyoga, S., Ndila, C., Mturi, N., Mwarumba, S., Mohammed, S., Mosobo, M., Alasoo, K., Rockett, K., Mentzer, A., Kwiatkowski, D., Hill, A., Maitland, K., Scott, J., & Williams, T. (2022). ELife, 11(11).
Higher-dose primaquine to prevent relapse of Plasmodium vivax malaria
Watson, J., & White, N. (2022). New England Journal of Medicine, 387(3), 282-283.
Definitions matter: heterogeneity of COVID-19 disease severity criteria and incomplete reporting compromise meta-analysis
Guérin, P., McLean, A., Rashan, S., Lawal, A., Watson, J., Strub-Wourgaft, N., & White, N. (2022). PLOS Global Public Health, 2(7).
Stopping prereferral rectal artesunate - a grave error
Watson, J., Warsame, M., Peto, T., Onyamboko, M., Fanello, C., Dondorp, A., & White, N. (2022). BMJ Global Health, 7(7).
Characterizing SARS-CoV-2 viral clearance kinetics to improve the design of antiviral pharmacometric studies
Watson, J., Kissler, S., Day, N., Grad, Y., & White, N. (2022). Antimicrobial Agents and Chemotherapy, 66(7).
The impact of malaria-protective red blood cell polymorphisms on parasite biomass in children with severe Plasmodium falciparum malaria
Uyoga, S., Watson, J., Wanjiku, P., Rop, J., Makale, J., Macharia, A., Kariuki, S., Nyutu, G., Shebe, M., Mosobo, M., Mturi, N., Rockett, K., Woodrow, C., Dondorp, A., Maitland, K., White, N., & Williams, T. (2022). Nature Communications, 13(1).
Pharmacometric and electrocardiographic evaluation of chloroquine and azithromycin in healthy volunteers
Chotsiri, P., Tarning, J., Hoglund, R., Watson, J., & White, N. (2022). Clinical Pharmacology & Therapeutics, 112(4), 824-835.
Improving the diagnosis of severe malaria in African children using platelet counts and plasma Pf HRP2 concentrations
Williams, T. (2022). Science Translational Medicine.
Methaemoglobinaemia and the radical curative efficacy of 8-aminoquinoline antimalarials
White, N., Watson, J., & Baird, J. (2022). British Journal of Clinical Pharmacology, 88(6), 2657-2664.
Risk of Plasmodium vivax recurrences follows a 30-70 rule and indicates relapse heterogeneity in the population
Stadler, E., Cromer, D., Mehra, S., Adekunle, A., Flegg, J., Anstey, N., Watson, J., Chu, C., Mueller, I., Robinson, L., Schlub, T., Davenport, M., & Khoury, D. (2022). In medRxiv.
Pharmacometric assessment of the in vivo antiviral activity of ivermectin in early symptomatic COVID-19
Schilling, W., Jittamala, P., Watson, J., Ekkapongpisit, M., Siripoon, T., Ngamprasertchai, T., Luvira, V., Pongwilai, S., Cruz, C., Callery, J., Boyd, S., Kruabkontho, V., Ngernseng, T., Tubprasert, J., Abdad, M., Piaraksa, N., Suwannasin, K., Hanboonkunupakarn, P., Hanboonkunupakarn, B., … White, N. (2022). In medRxiv.
The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: an individual patient data meta-analysis
Watson, J., Commons, R., Tarning, J., Simpson, J., Cuentas, A., Lacerda, M., Green, J., Koh, G., Chu, C., H Nosten, F., Price, R., Day, N., & White, N. (2022). In medRxiv.
The impact of malaria-protective red blood cell polymorphisms on parasite biomass in children with severe Plasmodium falciparum malaria
Uyoga, S., Watson, J., Wanjiku, P., Rop, J., Makale, J., Macharia, A., Kariuki, S., Nyutu, G., Shebe, M., Mosobo, M., Mturi, N., Rockett, K., Woodrow, C., Dondorp, A., Maitland, K., White, N., & Williams, T. (2022). In medRxiv.
Asexual stage synchronicity in symptomatic and asymptomatic falciparum malaria
Watson, J., & White, N. (2022). In medRxiv.
BIRC6 modifies risk of invasive bacterial infection in Kenyan children
Gilchrist, J., Kariuki, S., Watson, J., Band, G., Uyoga, S., Ndila, C., Mturi, N., Mwarumba, S., Mohammed, S., Mosobo, M., Rockett, K., Mentzer, A., Kwiatkowski, D., Hill, A., Maitland, K., Scott, A., & Williams, T. (2022). In medRxiv.
Clinical antiviral efficacy of remdesivir and casirivimab/imdevimab against the SARS-CoV-2 Delta and Omicron variants
Jittamala, P., Schilling, W., Watson, J., Luvira, V., Siripoon, T., Ngamprasertchai, T., Almeida, P., Ekkapongpisit, M., Cruz, C., Callery, J., Boyd, S., Anunsittichai, O., Hongsuwan, M., Singhaboot, Y., Pagornrat, W., Tuntipaiboontana, R., Kruabkontho, V., Ngernseng, T., Tubprasert, J., … White, N. (2022). In medRxiv.
Severe malaria, pascalian therapeutics, and the US Food and Drug Administration (FDA)
White, N., Watson, J., & Simpson, J. (2022). Clinical Infectious Diseases, 75(2), 358-358.
Falciparum malaria mortality in sub-Saharan Africa in the pretreatment era
Watson, J., White, N., & Dondorp, A. (2021). Trends in Parasitology, 38(1), 11-14.
The WHO guideline on drugs to prevent COVID-19: small numbers- big conclusions
Schilling, W., Callery, J., Chandna, A., Hamers, R., Watson, J., & White, N. (2021). Wellcome Open Research, 6, 71-71.
Determinants of primaquine and carboxyprimaquine exposures in children and adults with Plasmodium vivax malaria
Chu, C., Watson, J., Phyo, A., Win, H., Yotyingaphiram, W., Thinraow, S., Soe, N., Aung, A., Wilaisrisak, P., Kraft, K., Imwong, M., Hanpithakpong, W., Blessborn, D., Tarning, J., Proux, S., Ling, C., Nosten, F., & White, N. (2021). Antimicrobial Agents and Chemotherapy, 65(11).
Determinants of primaquine and carboxyprimaquine exposures in children and adults with Plasmodium vivax malaria
Chu, C., Watson, J., Phyo, A., Win, H., Yotyingaphiram, W., Thinraow, S., Soe, N., Aung, A., Wilaisrisak, P., Puaprasert, K., Imwong, M., Hanpithakpong, W., Blessborn, D., Tarning, J., Proux, S., Ling, C., Nosten, F., & White, N. (2021). In medRxiv.